IDEXX Laboratories, Inc. $IDXX Stock: Americana Partners LLC Lowers Stake

Key Points

• Americana Partners cut its IDEXX Laboratories stake by 45.6% in the third quarter, selling 3,122 shares and retaining 3,723 shares valued at approximately $1.94 million. Institutional investors and hedge funds collectively own 87.84% of the company.
• IDEXX reported stronger-than-expected quarterly results, with EPS of $4.27 versus the $3.94 consensus estimate and revenue of $1.22 billion. Revenue increased 9.7% year over year, and the company issued fiscal 2026 EPS guidance of $14.69–$14.94.
• The stock opened at $551.21 and has declined 4.3%, trading well below its 12-month high of $769.98. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $721.67, although several firms recently lowered their targets.

Americana Partners LLC reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 45.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,723 shares of the company's stock after selling 3,122 shares during the quarter. Americana Partners LLC's holdings in IDEXX Laboratories were worth $1,944,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of IDEXX Laboratories by 4.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company's stock worth $479,844,000 after acquiring an additional 39,700 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company's stock worth $471,335,000 after acquiring an additional 288,471 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in IDEXX Laboratories by 4.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company's stock valued at $322,145,000 after acquiring an additional 23,582 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company's stock valued at $211,146,000 after purchasing an additional 197,808 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company's stock, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.79% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Down 4.3%

IDXX opened at $551.21 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company's 50-day moving average price is $534.27 and its two-hundred day moving average price is $574.09. The stock has a market cap of $43.42 billion, a price-to-earnings ratio of 38.76 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. BTIG Research dropped coverage on IDEXX Laboratories in a report on Friday. They set a "buy" rating for the company. Barclays dropped their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings raised IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Finally, UBS Group lowered their price target on IDEXX Laboratories from $670.00 to $627.00 and set a "neutral" rating for the company in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $721.67.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.